Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
Esteban Cruz, Veysel KayserSchool of Pharmacy, The University of Sydney, Sydney, NSW, AustraliaAbstract: Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of a wide range of solid tumors. The targeted nature of these biotherapeutics has improved treatment outcomes...
Saved in:
Main Authors: | Cruz E, Kayser V |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/47df797738d34ba48a6a75b530a77069 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibody Therapies for Large B-Cell Lymphoma
by: Novo M, et al.
Published: (2021) -
Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice
by: Tan Y, et al.
Published: (2021) - Monoclonal antibodies in immunodiagnosis and immunotherapy
-
Photodynamic Priming Improves the Anti-Migratory Activity of Prostaglandin E Receptor 4 Antagonist in Cancer Cells In Vitro
by: Aaron J. Sorrin, et al.
Published: (2021) -
PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
by: Xu S, et al.
Published: (2018)